110 related articles for article (PubMed ID: 8826669)
1. Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients.
Vasquez EM; Pollak R
Clin Transplant; 1996 Jun; 10(3):294-7. PubMed ID: 8826669
[TBL] [Abstract][Full Text] [Related]
2. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3.
DeVault GA; Kohan DE; Nelson EW; Holman JM
Transplantation; 1994 Feb; 57(4):532-40. PubMed ID: 8116037
[TBL] [Abstract][Full Text] [Related]
3. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
4. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
[TBL] [Abstract][Full Text] [Related]
5. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383
[TBL] [Abstract][Full Text] [Related]
6. Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.
Bemelman FJ; Jansen J; van der Poll T; van Deventer SJ; ten Berge RJ
Nephrol Dial Transplant; 1994; 9(12):1786-90. PubMed ID: 7708265
[TBL] [Abstract][Full Text] [Related]
7. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
[TBL] [Abstract][Full Text] [Related]
8. OKT3 therapy increases cyclosporine blood levels.
Vasquez EM; Pollak R
Clin Transplant; 1997 Feb; 11(1):38-41. PubMed ID: 9067693
[TBL] [Abstract][Full Text] [Related]
9. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
Vasquez EM; Fabrega AJ; Pollak R
Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215
[No Abstract] [Full Text] [Related]
10. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
11. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome.
Eason JD; Pascual M; Wee S; Farrell M; Phelan J; Boskovic S; Blosch C; Mohler KM; Cosimi AB
Transplantation; 1996 Jan; 61(2):224-8. PubMed ID: 8600628
[TBL] [Abstract][Full Text] [Related]
12. Prevention of OKT3 nephrotoxicity after kidney transplantation.
Abramowicz D; De Pauw L; Le Moine A; Sermon F; Surquin M; Doutrelepont JM; Ickx B; Depierreux M; Vanherweghem JL; Kinnaert P; Goldman M; Vereerstraeten P
Kidney Int Suppl; 1996 Jan; 53():S39-43. PubMed ID: 8770989
[TBL] [Abstract][Full Text] [Related]
13. Effect of calcium-channel blocker on tumour necrosis factor alpha (TNF alpha) production in cyclosporin-treated renal transplant recipients.
Peces R; Urra JM
Nephrol Dial Transplant; 1995; 10(6):871-3. PubMed ID: 7566619
[TBL] [Abstract][Full Text] [Related]
14. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients.
Leimenstoll G; Zabel P; Schroeder P; Schlaak M; Niedermayer W
Transplant Proc; 1993 Feb; 25(1 Pt 1):561-3. PubMed ID: 8438414
[No Abstract] [Full Text] [Related]
15. Increased dermal expression of ICAM-1 and VCAM-1 after administration of OKT3 in man.
Buysmann S; van Diepen FN; Surachno S; Pals ST; ten Berge RJ
Clin Nephrol; 1996 Aug; 46(2):84-91. PubMed ID: 8869784
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
17. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
First MR; Schroeder TJ; Hariharan S
Transplant Proc; 1993 Apr; 25(2 Suppl 1):25-6. PubMed ID: 8465417
[No Abstract] [Full Text] [Related]
18. OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody.
Chatenoud L
Transplant Proc; 1993 Apr; 25(2 Suppl 1):47-51. PubMed ID: 8465425
[No Abstract] [Full Text] [Related]
19. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
Wissing KM; Morelon E; Legendre C; De Pauw L; LeBeaut A; Grint P; Maniscalki M; Ickx B; Vereerstraeten P; Chatenoud L; Kreis H; Goldman M; Abramowicz D
Transplantation; 1997 Oct; 64(7):999-1006. PubMed ID: 9381549
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline.
Schandené L; Gérard C; Crusiaux A; Abramowicz D; Velu T; Goldman M
Transplant Proc; 1993 Apr; 25(2 Suppl 1):55-6. PubMed ID: 8465427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
